



Review

Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of *Ginkgo biloba* leaf extract



Tuula Heinonen^{a,*}, Wilhelm Gaus^b

^aSchool of Medicine, Medisiinarin katu 3, FIN-33014 University of Tampere, Finland

^bInstitute for Epidemiology and Biometry, Medical Faculty, University of Ulm, Germany

ARTICLE INFO

Article history:

Received 20 August 2014

Received in revised form 13 October 2014

Accepted 27 October 2014

Available online 11 November 2014

Keywords:

Cross matching

Ginkgo biloba

EGb761[®], CAS 122933-57-7

Carcinogenicity

Adverse drug reaction

Clinical studies

ABSTRACT

Ginkgo biloba is one of the most widely used herbal remedies in Europe and the US. It may be purchased in different types of formulations, but most of the clinical studies have been performed with the controlled *G. biloba* extract EGb761[®]. Indications include Alzheimers disease, cardiovascular disease, dementia, memory loss, and cerebral ischemia. The pharmacological modes of action cover antioxidant effects, radical scavenging, inhibition of platelet activating factor, alterations in membrane fluidity (signal transduction), and inhibition of glucocorticoid synthesis. Due to the widespread and long-term use of *G. biloba* – about a million doses of EGb761[®] are sold per day – tolerability and safety are a crucial issue. Based on broad and long-term clinical use of *G. biloba* extracts, it is regarded as well tolerated in man.

Cross matching, a tool we introduced, combines different fields of knowledge and types of data to a consolidated result. In this article, we combine toxicological and clinical data and utilize other sources of information to assess tolerability and safety of *G. biloba*. It is well known that because of biological differences between animals and man or even between animal species, animal experiments do not necessarily mimic the effects in humans. Therefore, for adequate risk assessment, the relevance of non-clinical toxicological findings should be correlated with human data. The cross matching of toxicological data and results from clinical studies is possible because many toxicological and clinical studies are available on *G. biloba*. We give an in depth analysis of the modes of action in animals and describe toxicological studies with regard to metabolism, pharmacokinetics, genotoxicity, as well as carcinogenicity (e.g., the Technical Report TR 578 of the US National Toxicology Program). In addition, 75 clinical trials with high methodological quality are summarized. They included a total of 7115 patients treated with *G. biloba*. Based on this extensive amount of information, the broad variety of investigations, and their accordance we conclude that *G. biloba* extract is well tolerated and safe for humans.

© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/3.0/>).

Contents

1. Introduction	1
1.1. Importance of <i>Ginkgo biloba</i> extract	1
1.2. Components of <i>G. biloba</i>	1
1.3. Relevance of animal investigations	3
1.4. Possible adverse effects	3
2. Toxicity of <i>G. biloba</i> leaf extract	3
2.1. Commercial extracts	3
2.2. Pharmacological modes of action	4

Abbreviations: CYP, cytochrome P-450; GSH-transferase, glutathione-S-transferase; UDP-glucuronosyltransferase, uridine 5'-diphospho-glucuronosyltransferase; EGb761[®], *Ginkgo biloba* extract, CAS 122933-57-7; AhR, aryl hydrocarbon receptor; PXR, pregnane X receptor; CAR, constitutive androstane receptor; ADME, absorption, distribution, metabolism, excretion.

* Corresponding author. Tel. +358 40 9030086.

E-mail address: tuula.heinonen@uta.fi (T. Heinonen).

<http://dx.doi.org/10.1016/j.tox.2014.10.013>

0300-483X/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/3.0/>).

2.2.1.	Components	4
2.2.2.	Flavonoids	4
2.3.	Hepatic metabolism	4
2.3.1.	Mouse	4
2.3.2.	Rat	5
2.3.3.	Human	5
2.4.	Pharmacokinetics of <i>G. biloba</i> leaf extract	6
2.4.1.	Absorption	6
2.4.2.	Mouse	6
2.4.3.	Rat	6
2.4.4.	Human	6
2.5.	Carcinogenicity	7
2.5.1.	Carcinogenicity studies with EGb761 [®]	7
2.5.2.	Genotoxic carcinogenic risk	9
2.5.3.	Epigenetic carcinogenic risk	10
3.	Clinical tolerability and safety of <i>G. biloba</i> leaf extract	11
3.1.	Available information	11
3.1.1.	Knowledge on <i>G. biloba</i> leaf extracts	11
3.1.2.	Languages	11
3.1.3.	Clinical studies on <i>G. biloba</i>	11
3.2.	Tolerability and safety of <i>G. biloba</i> in clinical studies	11
3.2.1.	Indications for <i>G. biloba</i>	11
3.2.2.	Number of patients	11
3.2.3.	Tolerability and safety issues reported	13
3.3.	EMA assessment report and Cochrane reviews	13
3.3.1.	EMA assessment report	13
3.3.2.	Cochrane reviews on <i>G. biloba</i>	13
3.4.	Methodological considerations	13
3.4.1.	Error type I and type II	13
3.4.2.	Meta-analysis for tolerability and safety	14
3.4.3.	Adverse events observed	14
3.4.4.	Hypothesis generation	14
3.4.5.	Event rate	14
3.4.6.	Confidence interval for an event rate	14
3.4.7.	Confidence interval for an event rate of zero	14
3.4.8.	Interpretation of the computed confidence interval	15
3.4.9.	Number needed to harm	15
4.	Cross matching of toxicological, clinical, and additional other data	16
4.1.	Publication bias for safety of <i>G. biloba</i>	16
4.2.	Poor relationship of toxicological and clinical data	16
4.3.	Homogenous variance	16
4.4.	Toxicological results	16
4.5.	Clinical results	16
4.6.	Independence of observations	16
4.7.	Long traditional use of <i>G. biloba</i>	16
4.8.	Use of <i>G. biloba</i> today	16
4.9.	Four sources for cross matching	16
4.10.	Failure for hypothesis generation	16
4.11.	Absence of evidence is not an evidence of absence (Altmann and Bland, 1995)	16
5.	Final conclusion	17
	Conflict of interest	17
	Transparency document	17
	Acknowledgements	17
	References	17

1. Introduction

1.1. Importance of Ginkgo biloba extract

Extracts from *Ginkgo biloba* leaves have a long history, and today *G. biloba* is one of the most commonly used herbal medicinal products in Europe and in the US (EMA/HMPC/321095/2012, 2014; Saper, 2014). The extract taken most is the standardized extract EGb761[®]. *G. biloba* leaf extract is available as film-coated tablets, oral liquids, and injectable solutions. In Europe *G. biloba* extract is primarily regulated as herbal medicine, but in the US as a dietary supplement sold with health claims. *G. biloba* extract is used for diseases such as Alzheimer's disease, cardiovascular disease,

dementia, memory loss, and cerebral ischemia (Pereira et al., 2013; Diamond and Bailey, 2013; Herrschaft et al., 2012). The pharmacological modes of action include antioxidant effects, radical scavenging, inhibition of platelet activating factor, alterations in membrane fluidity (signal transduction), and inhibition of glucocorticoid synthesis (Pereira et al., 2013; Diamond and Bailey, 2013).

1.2. Components of *G. biloba*

A plant extract contains several chemical constituent types. Each component may possess different modes of action related to pharmacological and toxicological effects. Therefore, when assessing the risk of *G. biloba* leaf extract to humans a separate analysis of

Download English Version:

<https://daneshyari.com/en/article/5859184>

Download Persian Version:

<https://daneshyari.com/article/5859184>

[Daneshyari.com](https://daneshyari.com)